CXCL16 and neoplasm: In RCC, the expression of CXCL16 and its cognate receptor CXCR6 also associates with better survival outcomes in patients; however, neither has been linked with VHL loss or tumor-infiltrating lymphocyte (TIL) infiltration (35).